Section 4: Clinical Pharmacy Services

4CPS-141

USE OF ADALIMUMAB IN PATIENTS WITH HIDRADENITIS SUPPURATIVA

4CPS-133

RESPONSE TO VEMURAFENIB-COBIMETINIB WITH REDUCED DOSES IN A PATIENT WITH METASTASIC MELANOMA: CONCERNING A CASE

4CPS-132

LEVEL OF EVIDENCE AND DEGREE OF RECOMMENDATION OF INTRAVENOUS IMMUNOGLOBULIN IN AUTO-IMMUNE NEUROLOGICAL DISEASES

4CPS-130

USE OF NON-SPECIFIC IMMUNOGLOBULINS IN BURNED PAEDIATRIC PATIENTS: VALIDATION OF THE PROTOCOL OF A TERTIARY HOSPITAL

4CPS-110

IMPACT OF PATIENTS’ CONDITIONS ON THE EFFECTIVENESS AND SAFETY OF ERLOTINIB IN PANCREATIC CANCER

4CPS-109

EXPERIENCE OF REGORAFENIB USE IN METASTATIC COLORECTAL CANCER

4CPS-104

EFFECTIVENESS AND SAFETY OF CABAZITAXEL IN CASTRATION-RESISTANT METASTATIC PROSTATE CANCER

4CPS-103

SECOND-GENERATION TYROSIN KINASE INHIBITORS IN FRONT-LINE THERAPY. COMPARING RESPONSES

4CPS-093

LONG-TERM EFFICACY OF SECOND-GENERATION DIRECT-ACTING ANTIVIRAL AGENTS (DAAS-2) FOR HCV TREATMENT: A META-ANALYSIS

4CPS-090

EMTRICITABINE/ELVITEGRAVIR/COBICISTAT/TENOFOVIR: EFFECTS ON LIPID METABOLISM AND RENAL FUNCTION

4CPS-088

DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION: A REAL-WORLD DATA ANALYSIS

4CPS-083

EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS ON DARUNAVIR/COBICISTAT MONOTHERAPY TREATMENT

4CPS-082

EVALUATION OF EFFECTIVENESS OF DARUNAVIR/ COBICISTAT MONOTHERAPY IN HIV PATIENTS

4CPS-080

HIV POST-EXPOSURE PROPHYLAXIS PROTOCOL

4CPS-067

ASSESSMENT OF THE EFFECTIVENESS OF USING VANCOMYCIN IN PATIENTS UNDERGOING HAEMODYALISIS

Pages